Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone for Hypokalemia in Continuous Ambulatory Peritoneal Dialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 19, Issue 1, 2015, Pages 81-86

  Yongsiri, Somchai ^a   Thammakumpee, Jiranuch ^b   Prongnamchai, Suriya ^a   Tengpraettanakorn, Pechngam ^a   Chueansuwan, Rachaneeporn ^a   Tangjaturonrasme, Siriporn ^a   Dinchuthai, Pakaphan ^a  

^a BURAPHA UNIVERSITY   (Thailand)

^b CHONBURI HOSPITAL   (Thailand)

Author keywords

End stage renal disease; Hypokalemia; Peritoneal dialysis; Spironolactone

Indexed keywords

ALBUMIN; CALCIUM; MAGNESIUM; PHOSPHORUS; PLACEBO; POTASSIUM; SODIUM; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ATAXIA; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INCREASED APPETITE; MAGNESIUM BLOOD LEVEL; MALE; PERITONEAL FLUID; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; ULTRAFILTRATION; URINE VOLUME; ADVERSE EFFECTS; BLOOD; BLOOD ANALYSIS; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; BLOOD CHEMICAL ANALYSIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; REFERENCE VALUES; RISK ASSESSMENT; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84922654032     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12219     Document Type: Article

References (21)

1. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol 2012;23:533-544.
2. Zanger R. Hyponatremia and hypokalemia in patients on peritoneal dialysis. Semin Dial 2010;23:575-580.
3. Khan AN, Bernardini J, Johnston JR, Piraino B. Hypokalemia in peritoneal dialysis patients. Perit Dial Int 1996;16:652.
4. Szeto C-C, Chow K-M, Kwan BC-H etal. Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication. Am J Kidney Dis 2005;46:128-135.
5. Chuang Y-W, Shu K-H, Yu T-M, Cheng C-H, Chen C-H. Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. Nephrol Dial Transplant 2009;24:1603-1608.
6. Baker WL, White WB. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012;46:889-894.
7. Taheri S, Mortazavi M, Pourmoghadas A, Seyrafian S, Alipour Z, Karimi S. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012;23:507-512.
8. Vukusich A, Kunstmann S, Varela C etal. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin. J Am Soc Nephrol 2010;5:1380-1387.
9. Ito Y, Mizuno M, Suzuki Y etal. Long-Term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 2014;25:1094-1102.
10. Beermann B. Aspects on pharmacokinetics of some diuretics. Acta. Pharmacol Toxicol 1984;54(Suppl 1):17-29.
11. Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001;37:337-342.
12. Musso CG. Potassium metabolism in patients with chronic kidney disease. Part II: patients on dialysis (stage 5). Int Urol Nephrol 2004;36:469-472.
13. Coester AM, Struijk DG, Smit W, de Waart DR, Krediet RT. The cellular contribution to effluent potassium and its relation to free water transport during peritoneal dialysis. Nephrol Dial Transplant 2007;22:3593-3600.
14. Mathialahan T, Maclennan KA, Sandle LN, Verbeke C, Sandle GI. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol 2005;206:46-51.
15. Sørensen MV, Matos JE, Sausbier M etal. Aldosterone increases KCa1.1 (BK) channel-mediated colonic K+ secretion. J Physiol 2008;586:4251-4264.
16. Furuya R, Kumagai H, Sakao T, Maruyama Y, Hishida A. Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis. Nephron 2002;92:576-581.
17. Phakdeekitcharoen B, Leelasa-nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 2004;44:738-746.
18. Covic A, Gusbeth-Tatomir P, Goldsmith DJA. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 2006;21:854-858.
19. Pitt B, Zannad F, Remme WJ etal. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;2:709-717.
20. Juurlink DN, Mamdani MM, Lee DS etal. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551.
21. Papadimitriou M, Vyzantiadis A, Milionis A, Memmos D, Metaxas P. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Syst 1983;1:197-205.